Today, I requested and received a link to the Cypress presentation in Boston yesterday by Dr. Michael Hufford. I listened to the whole thing and, while Indaflex was only mentioned as "our topical NSAID", his presentation was really about a fiber myalgia drug although it included quite a bit about their reasons for buying Proprius. So, I had to feel pretty good about Hufford's level of intelligence and competence. Cynic that I am, I was suspicious about his previous explanation of the lack of a Phase lll launch. Now, I feel that they are extremely thorough and will get the job done to launch Indaflex. Here's the link:
http://www.corporate-ir.net/ireye/co...
